Trial · NCT05681884
Safety and Efficacy of Faricimab in Patients With NPDR
NCT05681884, Phase 2, Completed, Greater Houston Retina Research
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy of Faricimab in Patients With NPDR. Trials, record NCT05681884. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05681884
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy of Faricimab in Patients With NPDR
- NCT number
- NCT05681884
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 179 participants, actual
- Lead sponsor
- Greater Houston Retina Research
- Conditions
- Non-Proliferative Diabetic Retinopathy
- Interventions
- Faricimab
- First posted
- 2023-01-12
- Last updated
- 2026-03-20
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Primary Objective | 48 weeks | Analyze the change in the area of retinal non-perfusion (RNP) within the macula over 48 weeks using ultrawide-field fluorescein angiography (UWFA) within eyes that have NPDR. |
| Primary | Primary Objective | 48 weeks | Analyze the change in the area of retinal non-perfusion (RNP) outside the macula over 48 weeks using ultrawide-field fluorescein angiography (UWFA) within eyes that have NPDR. |
| Secondary | Change in area of RNP | Baseline through week 96 | Change in area of RNP, as assessed by a central reading center; linear regression of change in area of RNP (dependent variable) between the monthly faricimab and observation groups, adjusted for age, sex, and disease severity as defined by Baseline ETDRS |
| Secondary | Change in area of RNP within the macula | Baseline through week 48 and from baseline through week 96 | Change in area of RNP within the macula, as assessed by ultrawide-field fluorescein; linear regression of change in area of RNP (dependent variable) between the monthly faricimab and observation groups, adjusted for age, sex, and disease severity as defined by Baseline ETDRS |
| Secondary | Change in area of RNP outside of the macula | Baseline through week 48 and from baseline through week 96 | Change in area of RNP outside of the macula, as assessed by ultrawide-field fluorescein from baseline to week 96; linear regression of change in area of RNP (dependent variable) between the monthly faricimab and observation groups, adjusted for age, sex, and disease severity as defined by Baseline ETDRS |
| Secondary | Percentage of subjects with disease | Baseline through week 96 | Percentage of subjects with neovascularization and/or vitreous hemorrhage and/or DME |
| Secondary | Mean change in ETDRS | Baseline through week 48 and from baseline through week 96 | Mean change in ETDRS BCVA |
| Secondary | Mean change in CST | Baseline through week 48 and from baseline through week 96 | Mean change in CST |
| Secondary | Contrast Sensitivity | Baseline through Week 48 and from baseline through week 96 | Contrast sensitivity as measured using the quantitative Contrast Sensitivity Function (qCSF) testing on the Manifold Contrast Vision |
| Secondary | Natural History of RNP | Baseline through Week 48 and from baseline through week 96 | Natural history of RNP through detection of apoptosing retinal cells (DoARC) imaging |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41587134 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Contrast Sensitivity Test | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05681884
GET https://conductscience.org/api/trials/v1/NCT05681884/registered